ChromaDex Co. (NASDAQ:CDXC) Short Interest Update

ChromaDex Co. (NASDAQ:CDXC - Get Free Report) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 1,480,000 shares, a growth of 12.1% from the March 31st total of 1,320,000 shares. Based on an average daily volume of 309,600 shares, the days-to-cover ratio is currently 4.8 days. Approximately 3.3% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CDXC. StockNews.com began coverage on ChromaDex in a research report on Sunday, March 3rd. They set a "strong-buy" rating on the stock. Roth Mkm increased their price target on ChromaDex from $4.25 to $6.00 and gave the stock a "buy" rating in a research report on Tuesday, April 9th.

Hedge Funds Weigh In On ChromaDex

Several hedge funds and other institutional investors have recently made changes to their positions in the company. International Assets Investment Management LLC lifted its position in shares of ChromaDex by 43.0% in the fourth quarter. International Assets Investment Management LLC now owns 28,600 shares of the company's stock valued at $410,000 after acquiring an additional 8,600 shares in the last quarter. Gabelli Funds LLC lifted its position in ChromaDex by 9.1% during the third quarter. Gabelli Funds LLC now owns 180,000 shares of the company's stock worth $263,000 after buying an additional 15,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in ChromaDex by 121.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,031 shares of the company's stock worth $121,000 after buying an additional 45,618 shares in the last quarter. Gamco Investors INC. ET AL lifted its position in ChromaDex by 26.5% during the third quarter. Gamco Investors INC. ET AL now owns 259,850 shares of the company's stock worth $379,000 after buying an additional 54,500 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC purchased a new position in ChromaDex during the fourth quarter worth approximately $118,000. Hedge funds and other institutional investors own 15.41% of the company's stock.

ChromaDex Stock Up 3.4 %

Shares of NASDAQ CDXC traded up $0.12 during midday trading on Wednesday, hitting $3.66. The stock had a trading volume of 140,869 shares, compared to its average volume of 257,939. The company has a market capitalization of $276.40 million, a PE ratio of -52.28 and a beta of 1.99. The stock has a 50 day simple moving average of $3.00 and a 200-day simple moving average of $1.99. ChromaDex has a 1 year low of $1.25 and a 1 year high of $4.65.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.